Global Cancer Monoclonal Antibodies Market Report 2021 – Trends, Share, Size, Growth, Opportunity and Forecast to 2026 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Cancer Monoclonal Antibodies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026” report has been added to ResearchAndMarkets.com’s offering.
The global cancer monoclonal antibodies market exhibited moderate growth during 2015-2020. Looking forward, the publisher expects the global cancer monoclonal antibodies market to grow at a CAGR of 4.19% during 2021-2026.
The increasing prevalence of cancer across the globe is one of the key factors driving the growth of the market. In comparison to traditionally used non-targeted therapies, such as chemotherapy, monoclonal antibodies have reduced side-effects on the patient’s body and can also be used for the treatment of autoimmune and inflammatory diseases.
Furthermore, widespread adoption of cost-efficient biosimilar monoclonal antibodies by medical practitioners and oncologists is also providing a boost to the market growth. With technological advancements in gene sequencing and target gene selection, these antibodies can be modified to have similar properties to that of a pharmaceutical drug.
They have the same efficiency but are available at reduced prices than the original medicine, which aids in enhancing the cost-efficiency of the treatment, thereby contributing to the increasing demand for the product across the globe.
Other factors, including rising preference for personalized medicines, extensive research and development (R&D) activities and significant improvements in the healthcare infrastructure, are projected to drive the market further.
Key Questions Answered in This Report:
- How has the global cancer monoclonal antibodies market performed so far and how will it perform in the coming years?
- What are the key regional markets?
- What has been the impact of COVID-19 on the global cancer monoclonal antibodies market?
- What is the breakup of the market based on the antibody type?
- What is the breakup of the market based on the medication type?
- What is the breakup of the market based on the application?
- What is the breakup of the market based on the end-user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global cancer monoclonal antibodies market and who are the key players?
- What is the degree of competition in the industry?
Companies Mentioned
- AbbVie Inc.
- Amgen Inc.
- Bristol-Myers Squibb Company
- Eli Lilly
- Company
- Genmab A/S
- GlaxoSmithKline Plc.
- Johnson & Johnson
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
- Roche Holding AG
- Seattle Genetics Inc.
- Spectrum Pharmaceuticals Inc.
Breakup by Antibody Type:
- Murine Antibodies
- Chimeric Antibodies
- Humanized Antibodies
- Others
Breakup by Medication Type:
- Bevacizumab (Avastin)
- Rituximab (Rituxan)
- Trastuzumab (Herceptin)
- Cetuximab (Erbitux)
- Panitumumab (Vectibix)
- Others
Breakup by Application:
- Breast Cancer
- Blood Cancer
- Liver Cancer
- Brain Cancer
- Colorectal Cancer
- Others
Breakup by End-User:
- Hospitals and Clinics
- Pharmacies
- Research Laboratories
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Latin America
- Brazil
- Mexico
- Middle East and Africa
For more information about this report visit https://www.researchandmarkets.com/r/psqae6
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
